Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Paracetamol dosing errors can cause acute liver injury, with potentially toxic doses only slightly above the therapeutic range. This study aimed to characterise unintentional paracetamol overdose reported to an Australian poisons centre, including time trends, demographics, types of dosing errors, and outcomes.
Methods: Records regarding paracetamol dosing errors for individuals aged ≥12 years were extracted from the New South Wales Poisons Information Centre database, January 2017 to June 2023. Data from 2021 underwent an in-depth screening of free text case notes to examine: dose, duration, products involved, reasons for ingestion and outcomes including hospitalisation, treatment, liver transplantations and deaths. Where possible, complete outcome data were obtained from medical records of New South Wales hospitalised cases in 2021.
Results: There were 14,380 exposures due to paracetamol dosing errors (predominantly self-administered, median age 43 years, 62.6% female), with an average yearly increase of 2.5% (95% CI 1.6-3.8%; p < 0.0001). The in-depth analysis of exposures recorded during 2021 revealed 1899 exposures (median age 46 years, 63.4% female) with 26.8% requiring hospitalisation. Immediate- and modified-release formulations were highly implicated. Multiple paracetamol-containing products were ingested in approximately 20% of exposures. Hospitalised exposures were associated with paracetamol use for dental pain and ingested higher doses for longer durations. Over half of those hospitalised (52%) were treated with the antidote (N-acetylcysteine), and 6% of exposures developed hepatotoxicity.
Conclusion: Paracetamol dosing errors continue to occur, with relatively high rates of hospitalisation and liver injury. Many hospitalisations involved use for dental pain. Possible preventative measures include ingredient name prominence and increased education on appropriate dosing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554734 | PMC |
| http://dx.doi.org/10.1007/s40264-024-01472-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Model-Informed Precision Dosing of Vancomycin in Chinese Adult Patients Receiving Renal Replacement Therapy: Systematic Evaluation of Published Pharmacokinetic Models and Dosing Regimen Simulations.
Int J Antimicrob Agents
September 2025
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan
Objectives: The pharmacokinetics of renally cleared vancomycin are significantly altered in critically ill patients undergoing renal replacement therapy (RRT), affecting the achievement of therapeutic targets. We evaluated the predictive performance of RRT patient-based PopPK models for model-informed precision dosing and subsequently simulated optimal dosing regimens for this population.
Methods: Six adult PopPK models were systematically identified and evaluated using a dataset of 226 concentrations from 23 adult patients on RRT from two study centers.
Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint-Based Drop-The-Losers Design.
Stat Med
September 2025
Biostatistics and Data Management, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
Typical phase 1 oncology studies identify the maximum tolerated dose as the "optimal" dose for subsequent phases. With the advancement of molecular targeted agents and immunotherapies, however, evaluating two or more doses has become increasingly critical for dose selection. Such evaluation is often done in phase 2 studies in a randomized manner.
View Article and Find Full Text PDFEffect of sex on the progression of non-motor symptoms in Parkinson's disease: A registry-based cohort study.
Neurologia (Engl Ed)
September 2025
Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain; Department of Neurology, Cruces University Hospital, Osakidetza, Barakaldo, Bizkaia, Spain.
Introduction: Differences in the trajectory of non-motor symptoms (NMS) between male and female Parkinson's disease (PD) patients over the course of the disease are not well-understood.
Methods: PD patients were rated with Non-Motor Symptom Scale (NMSS) at two time points with a median follow-up of 3.8 years (IQR 2.
Beyond Mean Absolute Relative Difference (MARD): Rethinking Continuous Glucose Monitoring (CGM) Evaluation for Real-World Diabetes Care.
Cureus
September 2025
Department of Internal Medicine, Civil Hospital of Ovada, Ovada, ITA.
Continuous glucose monitoring (CGM) has transformed diabetes mellitus management, evolving from a supportive monitoring tool to a central pillar of care. For people with type 1 diabetes and many insulin-treated individuals with type 2 diabetes, CGM now directly informs treatment decisions, especially when integrated with automated insulin delivery (AID) systems. In these hybrid closed-loop systems, sensor data drives real-time insulin adjustments, meaning that accuracy is not just a matter of measurement quality; it is a matter of patient safety.
View Article and Find Full Text PDFIV loop diuretics remain the cornerstone of treatment for acute decompensated heart failure (ADHF). Although previous meta-analyses have compared continuous infusion and intermittent bolus dosing of IV loop diuretics, their respective renal effects remain unclear. Given the prognostic significance of worsening renal function (WRF) or acute kidney injury in ADHF, evaluating the renal safety of different diuretic regimens is essential.
View Article and Find Full Text PDF